References
- Walter RB, Othus M, Burnett AK, Lowenberg B, Kantarjian HM, Ossenkoppele GJ, et al. Resistance prediction in aml: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOC and MD Anderson Cancer Center. Leukemia. 2014;29:312–20.
- Available from: https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx
- Acute Myeloid Leukemia. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Version 1; 2016. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
- Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.10.1182/blood-2009-07-235358
- Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol. 2013;26:253–9.10.1016/j.beha.2013.10.005
- Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66.10.1182/blood-2006-06-025627
- Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission. Cancer. 2005;103(8):1652–8.10.1002/(ISSN)1097-0142
- Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission. JAMA. 2009;301(22):2349–61.10.1001/jama.2009.813
- Tran H, Yang D. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults. Ann Pharmacother. 2012;46:89–96.10.1345/aph.1Q295
- Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma. 2007;48:1922–30.10.1080/10428190701545644
- Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011;155(2):182–9.10.1111/j.1365-2141.2011.08831.x
- Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012;30:2492–2499.10.1200/JCO.2011.37.9743
- Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the ınternational working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–9.10.1200/JCO.2003.04.036
- US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009 (v.403: June 14, 2010).
- Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-ıntensity conditioning regimen workshop: defining the dose spectrum. Report of a Workshop convened by the center for ınternational blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9.10.1016/j.bbmt.2008.12.497
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.10.3322/caac.21208
- Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, et al. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol. 2012;87:1047–51.10.1002/ajh.v87.12
- Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes J, Estey E, et al. Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105:940–947.
- Shah A, Andersson TM, Rachet B, Björkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971–2006: a population-based study. Br J Haematol. 2013;162:509–16.10.1111/bjh.2013.162.issue-4
- Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary ınduction failure. J Clin Oncol. 2010;28(23):3730–8.10.1200/JCO.2010.28.8852
- Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long- term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy andreduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108:1092–9.10.1182/blood-2005-10-4165